Your browser doesn't support javascript.
loading
Computational design of anti-CRISPR proteins with improved inhibition potency.
Mathony, Jan; Harteveld, Zander; Schmelas, Carolin; Upmeier Zu Belzen, Julius; Aschenbrenner, Sabine; Sun, Wei; Hoffmann, Mareike D; Stengl, Christina; Scheck, Andreas; Georgeon, Sandrine; Rosset, Stéphane; Wang, Yanli; Grimm, Dirk; Eils, Roland; Correia, Bruno E; Niopek, Dominik.
Afiliação
  • Mathony J; Synthetic Biology Group, BioQuant Center, University of Heidelberg, Heidelberg, Germany.
  • Harteveld Z; Digital Health Center, Berlin Institute of Health (BIH) and Charité, Berlin, Germany.
  • Schmelas C; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Upmeier Zu Belzen J; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Aschenbrenner S; Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany.
  • Sun W; BioQuant Center and Cluster of Excellence CellNetworks at Heidelberg University, Heidelberg, Germany.
  • Hoffmann MD; Synthetic Biology Group, BioQuant Center, University of Heidelberg, Heidelberg, Germany.
  • Stengl C; Digital Health Center, Berlin Institute of Health (BIH) and Charité, Berlin, Germany.
  • Scheck A; Health Data Science Unit, University Hospital Heidelberg, Heidelberg, Germany.
  • Georgeon S; Synthetic Biology Group, BioQuant Center, University of Heidelberg, Heidelberg, Germany.
  • Rosset S; Digital Health Center, Berlin Institute of Health (BIH) and Charité, Berlin, Germany.
  • Wang Y; Department of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Grimm D; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Eils R; Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Correia BE; Synthetic Biology Group, BioQuant Center, University of Heidelberg, Heidelberg, Germany.
  • Niopek D; Department of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nat Chem Biol ; 16(7): 725-730, 2020 07.
Article em En | MEDLINE | ID: mdl-32284602
Anti-CRISPR (Acr) proteins are powerful tools to control CRISPR-Cas technologies. However, the available Acr repertoire is limited to naturally occurring variants. Here, we applied structure-based design on AcrIIC1, a broad-spectrum CRISPR-Cas9 inhibitor, to improve its efficacy on different targets. We first show that inserting exogenous protein domains into a selected AcrIIC1 surface site dramatically enhances inhibition of Neisseria meningitidis (Nme)Cas9. Then, applying structure-guided design to the Cas9-binding surface, we converted AcrIIC1 into AcrIIC1X, a potent inhibitor of the Staphylococcus aureus (Sau)Cas9, an orthologue widely applied for in vivo genome editing. Finally, to demonstrate the utility of AcrIIC1X for genome engineering applications, we implemented a hepatocyte-specific SauCas9 ON-switch by placing AcrIIC1X expression under regulation of microRNA-122. Our work introduces designer Acrs as important biotechnological tools and provides an innovative strategy to safeguard CRISPR technologies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Engenharia de Proteínas / MicroRNAs / Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas / Sistemas CRISPR-Cas / Edição de Genes / Proteína 9 Associada à CRISPR Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Engenharia de Proteínas / MicroRNAs / Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas / Sistemas CRISPR-Cas / Edição de Genes / Proteína 9 Associada à CRISPR Idioma: En Ano de publicação: 2020 Tipo de documento: Article